Testing the drug pumitamig for recurrent glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with glioblastoma (WHO Grade IV) that has come back after previous treatment with radiation and temozolomide.
- You are able to swallow pills and keep them down.
- Your brain MRI shows at least one tumor that can be measured.
- You have not had more than one recurrence of your glioblastoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests an experimental oral drug called CT-179, which targets a protein involved in brain tumor growth. It may help people with glioblastoma, a type of brain cancer, when standard treatments have not worked or as part of initial treatment.
This trial tests whether using special MRI information to plan proton radiation, plus a drug called Avastin (bevacizumab), can help control recurrent glioblastoma (a fast-growing brain tumor) and improve outcomes. It mainly aims to treat tumor that has come back after prior standard radiation, using careful timing and imaging to target it safely.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.